Sale is live|00:00:00
Nirman AgriQ4 FY26

Nirman Agri

Q4 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

No

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 1
  • Nirman Agri Genetics targets a revenue growth of 150% to 200% annually for the next 5 years.
  • Current revenue stands at INR173 crores, with guidance to reach INR220-250 crores in FY25.
  • Expected revenue:
  • - INR432 crores in two years
  • - INR1,000 crores in the next two years
  • - Approximately INR2,000 crores in five years
  • No plan to reach INR20,000 crores by 2030 (clarified miscalculation).
  • Growth driven by expanding market share, increased production capacity from own processing plant, and new initiatives like Krushi Dham physical stores.
  • Operating margins expected to improve to 14%-15% with full utilization of new processing facility.
  • Growth will be sustainable and spread throughout the year despite seasonality.

Margin guidance

Category 3
  • Revenue growth guidance is strong, targeting 150% to 200% growth annually over the next five years.
  • The company expects to grow from around INR 200 crores currently to INR 2,000 crores in revenue within five years.
  • Net profit margins are projected to improve, aiming for 14-15% PAT margins, up from current 10-11%.
  • Full utilization of the company's own processing plant is expected to contribute to margin expansion in upcoming periods.
  • Q3 FY25 revenue rose 223% YoY, and net profit increased 114% YoY, signaling operational scalability and strong earnings potential.
  • No immediate fundraising planned; capital allocation will depend on future situation as the company scales.
  • Earnings per share (EPS) is expected to benefit from the growth in revenues and margins, reflecting sustainable profitability improvements.

Sign up free to read the full earnings analysis

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Nirman Agri and 1,400+ other companies.

Fundraise plans

No
  • Currently, Nirman Agri Genetics Limited has no immediate plans for fundraising through debt or equity.
  • Decisions on fundraising will be made depending on the situation at the relevant time.
  • The company is focused on its growth strategy and prefers to take fundraising decisions based on need as they scale.
  • There is no ongoing fundraising activity announced as of the February 27, 2025 conference call.

Order book

Yes
  • Current order book for Kharif season: INR 150 crores (unexecuted orders as of February 2025).
  • Current order book for Rabi season: INR 98 crores.
  • Combined order book (Kharif + Rabi): INR 248 crores approximately.
  • Order book expected to increase by April 2025.
  • Company standing on INR 173 crores revenue for 9 months FY25.
  • Expected to meet guidance of INR 220-250 crores revenue for full FY25.
  • Strong revenue growth indicating timely execution of order book.

Capex plans

Yes
  • The company has made a capex of about INR 3.5 crores for their factory.
  • The factory has a revenue potential of INR 500 crores with an expected PAT margin of around 15%.
  • No specific future capex plans were explicitly mentioned for new factories or expansions.
  • For the planned growth to INR 2,000 crores revenue in the next five years, no current fundraising or investment plans are in place; decisions will be made based on the situation at that time.
  • Krushi Dham physical stores are planned as a strategic initiative, with about 25 stores targeted initially, dependent on certifications and licensing.
  • The company aims to focus on certifications, licensing, and corporate governance improvements to support future growth.

How does Nirman Agri rank vs peers in Agricultural Food & other Products?

Pro feature
1Nirman Agri
Rev 1Mar 3

See full Agricultural Food & other Products sector rankings

Unlock with Pro

Want more stocks like Nirman Agri?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio